The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

The TBVPX-113 Study Team

Research output: Contribution to journalArticle

28 Scopus citations

Fingerprint Dive into the research topics of 'The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial'. Together they form a unique fingerprint.

Medicine & Life Sciences